Merck buys exclusive rights to Chinese company’s heart disease drug
Merck said it has signed a license to buy a heart disease drug from Chinese company Jiangsu Hengrui Pharmaceuticals in a deal worth $2 billion.
Under the deal, Merck will gain exclusive rights to develop, manufacture and sell the experimental oral heart disease drug HRS-5346 worldwide, excluding Greater China.
The drug, currently in a mid-phase study, belongs to a class of drugs that prevent the buildup of cholesterol, fats and proteins in the blood, which can restrict blood flow to vital organs and cause heart attacks, strokes and other cardiovascular diseases.
